Literature DB >> 22837097

A DNA-based candidate HIV vaccine delivered via in vivo electroporation induces CD4 responses toward the α4β7-binding V2 loop of HIV gp120 in healthy volunteers.

Jakub Kopycinski1, Hannah Cheeseman, Ambreen Ashraf, Dilbinder Gill, Peter Hayes, Drew Hannaman, Jill Gilmour, Josephine H Cox, Sandhya Vasan.   

Abstract

Administration of a clade C/B' candidate HIV-1 DNA vaccine, ADVAX, by in vivo electroporation (EP) was safe and more immunogenic than intramuscular administration without EP. The breadth and specificity of T-cell responses to full-length Env were mapped. Responses to multiple Env regions were induced, with most focusing on V3/C4 and V2 regions, including the α4β7 integrin-binding domain. The breadth of responses induced by this DNA vaccine regimen was comparable to that of viral-vectored vaccine regimens.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22837097      PMCID: PMC3428404          DOI: 10.1128/CVI.00327-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  28 in total

1.  Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.

Authors:  Will Fischer; Simon Perkins; James Theiler; Tanmoy Bhattacharya; Karina Yusim; Robert Funkhouser; Carla Kuiken; Barton Haynes; Norman L Letvin; Bruce D Walker; Beatrice H Hahn; Bette T Korber
Journal:  Nat Med       Date:  2006-12-24       Impact factor: 53.440

2.  Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B' recombinant.

Authors:  Yaoxing Huang; Zhiwei Chen; Wenyong Zhang; Deborah Gurner; Yang Song; David F Gardiner; David D Ho
Journal:  J Acquir Immune Defic Syndr       Date:  2008-04-01       Impact factor: 3.731

3.  Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.

Authors:  Nilu Goonetilleke; Stephen Moore; Len Dally; Nicola Winstone; Inese Cebere; Abdul Mahmoud; Susana Pinheiro; Geraldine Gillespie; Denise Brown; Vanessa Loach; Joanna Roberts; Ana Guimaraes-Walker; Peter Hayes; Kelley Loughran; Carole Smith; Jan De Bont; Carl Verlinde; Danii Vooijs; Claudia Schmidt; Mark Boaz; Jill Gilmour; Pat Fast; Lucy Dorrell; Tomas Hanke; Andrew J McMichael
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

4.  The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.

Authors:  Mark S de Souza; Silvia Ratto-Kim; Weerawan Chuenarom; Alexandra Schuetz; Somsak Chantakulkij; Bessara Nuntapinit; Anais Valencia-Micolta; Doris Thelian; Sorachai Nitayaphan; Punnee Pitisuttithum; Robert M Paris; Jaranit Kaewkungwal; Nelson L Michael; Supachai Rerks-Ngarm; Bonnie Mathieson; Mary Marovich; Jeffrey R Currier; Jerome H Kim
Journal:  J Immunol       Date:  2012-04-23       Impact factor: 5.422

5.  Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers.

Authors:  Shixia Wang; Jeffrey S Kennedy; Kim West; David C Montefiori; Scott Coley; John Lawrence; Siyuan Shen; Sharone Green; Alan L Rothman; Francis A Ennis; James Arthos; Ranajit Pal; Phillip Markham; Shan Lu
Journal:  Vaccine       Date:  2008-01-10       Impact factor: 3.641

6.  HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells.

Authors:  James Arthos; Claudia Cicala; Elena Martinelli; Katilyn Macleod; Donald Van Ryk; Danlan Wei; Zhen Xiao; Timothy D Veenstra; Thomas P Conrad; Richard A Lempicki; Sherry McLaughlin; Massimiliano Pascuccio; Ravindra Gopaul; Jonathan McNally; Catherine C Cruz; Nina Censoplano; Eva Chung; Kristin N Reitano; Shyam Kottilil; Diana J Goode; Anthony S Fauci
Journal:  Nat Immunol       Date:  2008-02-10       Impact factor: 25.606

7.  Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response.

Authors:  Ryan M Troyer; John McNevin; Yi Liu; Shao Chong Zhang; Randall W Krizan; Awet Abraha; Denis M Tebit; Hong Zhao; Santiago Avila; Michael A Lobritz; M Juliana McElrath; Sylvie Le Gall; James I Mullins; Eric J Arts
Journal:  PLoS Pathog       Date:  2009-04-03       Impact factor: 6.823

8.  An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.

Authors:  Alexandre Harari; Pierre-Alexandre Bart; Wolfgang Stöhr; Gonzalo Tapia; Miguel Garcia; Emmanuelle Medjitna-Rais; Séverine Burnet; Cristina Cellerai; Otto Erlwein; Tristan Barber; Christiane Moog; Peter Liljestrom; Ralf Wagner; Hans Wolf; Jean-Pierre Kraehenbuhl; Mariano Esteban; Jonathan Heeney; Marie-Joelle Frachette; James Tartaglia; Sheena McCormack; Abdel Babiker; Jonathan Weber; Giuseppe Pantaleo
Journal:  J Exp Med       Date:  2008-01-14       Impact factor: 14.307

9.  Design and pre-clinical evaluation of a universal HIV-1 vaccine.

Authors:  Sven Létourneau; Eung-Jun Im; Tumelo Mashishi; Choechoe Brereton; Anne Bridgeman; Hongbing Yang; Lucy Dorrell; Tao Dong; Bette Korber; Andrew J McMichael; Tomás Hanke
Journal:  PLoS One       Date:  2007-10-03       Impact factor: 3.240

10.  The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion.

Authors:  Rogier W Sanders; Eelco van Anken; Alexei A Nabatov; I Marije Liscaljet; Ilja Bontjer; Dirk Eggink; Mark Melchers; Els Busser; Martijn M Dankers; Fedde Groot; Ineke Braakman; Ben Berkhout; William A Paxton
Journal:  Retrovirology       Date:  2008-01-31       Impact factor: 4.602

View more
  17 in total

1.  Skin Transfection Patterns and Expression Kinetics of Electroporation-Enhanced Plasmid Delivery Using the CELLECTRA-3P, a Portable Next-Generation Dermal Electroporation Device.

Authors:  Dinah H Amante; Trevor R F Smith; Janess M Mendoza; Katherine Schultheis; Jay R McCoy; Amir S Khan; Niranjan Y Sardesai; Kate E Broderick
Journal:  Hum Gene Ther Methods       Date:  2015-08       Impact factor: 2.396

2.  Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.

Authors:  Xiaohong Jiang; Tim J Dalebout; Igor S Lukashevich; Peter J Bredenbeek; David Franco
Journal:  J Gen Virol       Date:  2014-12-16       Impact factor: 3.891

3.  Clustered epitopes within a new poly-epitopic HIV-1 DNA vaccine shows immunogenicity in BALB/c mice.

Authors:  Nazli Jafarpour; Arash Memarnejadian; Mohammad Reza Aghasadeghi; Fatemeh Kohram; Haniyeh Aghababa; Nima Khoramabadi; Mehdi Mahdavi
Journal:  Mol Biol Rep       Date:  2014-05-20       Impact factor: 2.316

4.  Functional implications of the binding mode of a human conformation-dependent V2 monoclonal antibody against HIV.

Authors:  Brett Spurrier; Jared Sampson; Miroslaw K Gorny; Susan Zolla-Pazner; Xiang-Peng Kong
Journal:  J Virol       Date:  2014-01-29       Impact factor: 5.103

5.  A phase 1, randomized, controlled dose-escalation study of EP-1300 polyepitope DNA vaccine against Plasmodium falciparum malaria administered via electroporation.

Authors:  Paul Spearman; Mark Mulligan; Evan J Anderson; Andi L Shane; Kathy Stephens; Theda Gibson; Brooke Hartwell; Drew Hannaman; Nora L Watson; Karnail Singh
Journal:  Vaccine       Date:  2016-09-30       Impact factor: 3.641

6.  DNA Vaccination by Electroporation Amplifies Broadly Cross-Restricted Public TCR Clonotypes Shared with HIV Controllers.

Authors:  Madhura Mukhopadhyay; Moran Galperin; Mandar Patgaonkar; Sandhya Vasan; David D Ho; Alexandre Nouël; Mathieu Claireaux; Daniela Benati; Olivier Lambotte; Yaoxing Huang; Lisa A Chakrabarti
Journal:  J Immunol       Date:  2017-10-09       Impact factor: 5.422

7.  Development and Evaluation of an Ebola Virus Glycoprotein Mucin-Like Domain Replacement System as a New Dendritic Cell-Targeting Vaccine Approach against HIV-1.

Authors:  Zhujun Ao; Lijun Wang; Hiva Azizi; Titus Abiola Olukitibi; Gary Kobinger; Xiaojian Yao
Journal:  J Virol       Date:  2021-07-12       Impact factor: 5.103

8.  Elucidating the Kinetics of Expression and Immune Cell Infiltration Resulting from Plasmid Gene Delivery Enhanced by Surface Dermal Electroporation.

Authors:  Janess M Mendoza; Dinah H Amante; Gleb Kichaev; Christine L Knott; William B Kiosses; Trevor R F Smith; Niranjan Y Sardesai; Kate E Broderick
Journal:  Vaccines (Basel)       Date:  2013-08-28

9.  Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in Situ.

Authors:  Yen Cu; Kate E Broderick; Kaustuv Banerjee; Julie Hickman; Gillis Otten; Susan Barnett; Gleb Kichaev; Niranjan Y Sardesai; Jeffrey B Ulmer; Andrew Geall
Journal:  Vaccines (Basel)       Date:  2013-08-22

Review 10.  HIV DNA Vaccine: Stepwise Improvements Make a Difference.

Authors:  Barbara K Felber; Antonio Valentin; Margherita Rosati; Cristina Bergamaschi; George N Pavlakis
Journal:  Vaccines (Basel)       Date:  2014-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.